Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
University of North Carolina at Chapel Hill · Diabeteszentrum Bad Lauterberg · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
563
total citations
- FWCI
- 38.84
- Percentile
- 100%
- References
- 30
Citations per year
Authors
12- JBJohn B. Buse
University of North Carolina at Chapel Hill
- MAMichael A. Nauck
Diabeteszentrum Bad Lauterberg
- TFThomas Först
Institut für Klinische Forschung und Entwicklung
- WHWayne H.-H. Sheu
National Yang Ming Chiao Tung University, Taichung Veterans General Hospital
- SSSylvia Shenouda
Eli Lilly (United States)
Topics & keywords
Topics
Keywords
- Liraglutide
- Exenatide
- Medicine
- Type 2 diabetes
- Open label
- Duration (music)
- Diabetes mellitus
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.